Curis opens 11 sites for emavusertib combo in TakeAim CLL trial
Key takeaways
- Curis opens 11 sites for emavusertib combo in Take Aim CLL trial.
- The company also reaffirmed that dosing of the initial five patients is on track to take place by the end of July 2026, with study data anticipated in December 2026.
- The open-label trial will examine the dual inhibition strategy targeting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), which is considered a key driver in CLL pathology.
Curis opens 11 sites for emavusertib combo in Take Aim CLL trial. The open-label trial will examine the dual inhibition strategy targeting NF-k B. Credit: Gorodenkoff/Shutterstock.com. · Clinical Trials Arena · Gorodenkoff/Shutterstock.com. Salong Debbarma Mon, June 29, 2026 at 5:37 PM GMT+7 2 min read CRIS Curis has opened enrolment at 11 clinical sites for its Phase II Take Aim CLL trial to assess the oral small molecule inhibitor emavusertib, along with zanubrutinib, for patients with chronic lymphocytic leukaemia (CLL).
The company also reaffirmed that dosing of the initial five patients is on track to take place by the end of July 2026, with study data anticipated in December 2026.
The open-label trial will examine the dual inhibition strategy targeting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), which is considered a key driver in CLL pathology.